World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
66656
World Ranking
10643
National Ranking
328

Overview

Benjamin Solomon is affiliated with the Peter MacCallum Cancer Centre in Australia. Their research primarily focuses on medicine, with significant contributions to pulmonary and respiratory medicine, oncology, cancer research, molecular biology, and immunology.

The scientist's work extensively covers key topics in lung cancer, including treatments and mutations, diagnosis and treatment methods, and related research studies. Additional research topics include cancer immunotherapy and biomarkers, cancer genomics and diagnostics, colorectal cancer treatments and studies, and CAR-T cell therapy research.

Benjamin Solomon has authored several recent papers published in renowned journals. Notable publications include:

  • Lung cancer, 2021, The Lancet
  • First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer, 2020, New England Journal of Medicine
  • Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer, 2020, New England Journal of Medicine
  • Efficacy of Selpercatinib in RET -Altered Thyroid Cancers, 2020, New England Journal of Medicine
  • Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2023, Annals of Oncology

Collaborations have been an important part of their research, with frequent coauthors including Enriqueta Felip, Marliese Alexander, Alexander Drilon, Thomas John, and Ross A. Soo.

Benjamin Solomon's research has been published in various frequent venues which include the Journal of Thoracic Oncology, Journal of Clinical Oncology, Annals of Oncology, Lung Cancer, and Cancer Research.

Best Publications

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto

  • First-line crizotinib versus chemotherapy in ALK-positive lung cancer

    Benjamin J. Solomon;Tony Shu-kam Mok;Dong Wan Kim;Yi Long Wu

  • Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

    Alice T. Shaw;Beow Y. Yeap;Mari Mino-Kenudson;Subba R. Digumarthy

  • Comprehensive genomic profiles of small cell lung cancer

    Julie George;Jing Shan Lim;Se Jin Jang;Yupeng Cun

  • Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Sai Hong I. Ou;Yung Jue Bang;D. Ross Camidge

  • Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Ranee Mehra;Daniel S W Tan

  • Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

    Neal I. Lindeman;Philip T. Cagle;Dara L. Aisner;Maria E. Arcila

  • Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

    Martin Peifer;Lynnette Fernández-Cuesta;Martin L. Sos;Julie George

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

    Ryohei Katayama;Alice T. Shaw;Alice T. Shaw;Tahsin M. Khan;Tahsin M. Khan;Mari Mino-Kenudson

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

    J. Mazieres;A. Drilon;A. Lusque;L. Mhanna

  • Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

    Jonathan Weiss;Martin L. Sos;Danila Seidel;Martin Peifer

  • Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group Part 2 TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

    Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell

  • Prognostic Significance of p16INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial

    Danny Rischin;Richard J. Young;Richard Fisher;Stephen B. Fox

  • Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

    Lecia V. Sequist;Jean Charles Soria;Jonathan W. Goldman;Heather A. Wakelee

  • First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Todd M. Bauer;Filippo de Marinis;Enriqueta Felip

  • Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

    Benjamin J. Solomon;Benjamin Besse;Benjamin Besse;Todd M. Bauer;Enriqueta Felip

  • Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

    Daniel B. Costa;Alice T. Shaw;Sai-Hong I. Ou;Benjamin J. Solomon

Frequent Co-Authors

Alice T. Shaw
Alice T. Shaw Harvard University
D. Ross Camidge
D. Ross Camidge University of Colorado Anschutz Medical Campus
Danny Rischin
Danny Rischin Peter MacCallum Cancer Centre
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Benjamin Besse
Benjamin Besse University of Paris-Saclay
Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
Stephen B. Fox
Stephen B. Fox Peter MacCallum Cancer Centre
Gregory J. Riely
Gregory J. Riely Memorial Sloan Kettering Cancer Center
Grant A. McArthur
Grant A. McArthur Peter MacCallum Cancer Centre
Sai-Hong Ignatius Ou
Sai-Hong Ignatius Ou University of California, Irvine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in alternative routes within the healthcare field, several flexible online programs can help advance your career quickly and conveniently. Nurses seeking to expand their skills may benefit from programs such as rn to bsn online no clinicals, which allow registered nurses to earn their Bachelor of Science in Nursing without needing to complete additional clinical hours.

Those aiming for leadership roles can consider advanced degrees. The fastest online dnp programs are designed for working professionals who want to complete their Doctor of Nursing Practice in less time, while still maintaining high academic standards. Similarly, the shortest dnp program paths can make it achievable to earn a terminal nursing degree on an accelerated timeline.

If you’re interested in entering the nursing field faster, an accelerated lpn program offers a quick pathway to becoming a Licensed Practical Nurse, often through flexible online coursework.

These options provide opportunities for both entry-level and experienced healthcare professionals to advance their education and career prospects online, often with a faster completion time than traditional programs.

Best Scientists Citing Benjamin Solomon

Trending Scientists